• FirefoxUpgrade to the new Firefox »
  •  Dow Up0.13% Nasdaq Up0.70%

    Lexicon Pharmaceuticals, Inc. (LXRX)

    -NasdaqGS
    0.91 Up 0.01(1.09%) Dec 26, 4:00PM EST
    Add to Portfolio
    ProfileGet Profile for:
    Lexicon Pharmaceuticals, Inc.
    8800 Technology Forest Place
    The Woodlands, TX 77381
    United States - Map
    Phone: 281-863-3000
    Fax: 281-863-8088
    Website: http://www.lexpharma.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:149

    Business Summary 

    Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for human disease. Its drug development programs include LX4211, an orally-delivered small molecule compound that has completed two Phase II clinical trials for the treatment of type 2 diabetes patients, as well as an additional clinical trial for the treatment of type 2 diabetes patients with renal impairment; and completing a Phase II clinical trial for the treatment of type 1 diabetes patients. The company also develops telotristat etiprate or LX1032, an orally-delivered small molecule drug candidate, which has completed two Phase II clinical trials and is in a pivotal Phase III clinical trial for the treatment of carcinoid syndrome and ulcerative colitis. In addition, it develops LX1033, an orally-delivered small molecule compound that has completed Phase II clinical trial for the treatment of irritable bowel syndrome; LX2931, an orally-delivered small molecule compound, which has completed Phase II clinical trial for the treatment of rheumatoid arthritis; and LX7101, a topically-delivered small molecule compound that has completed Phase 1 clinical trial for the treatment of glaucoma. Further, the company’s preclinical development programs comprise LX2761, an orally-delivered small molecule compound for the treatment of diabetes. It has drug discovery and development collaborations with Bristol-Myers Squibb Company, Genentech, Inc., and Takeda Pharmaceutical Company Limited. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Lexicon Pharmaceuticals, Inc.

    Corporate Governance 
    Lexicon Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Dec 1, 2014 is 10. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 7; Compensation: 9.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Dr. Brian P. Zambrowicz Ph.D., 51
    Co-Founder, Chief Scientific Officer and Exec. VP
    413.00K0.00
    Mr. Jeffrey L. Wade J.D., 49
    Chief Financial Officer and Exec. VP of Corp. Devel.
    398.00K0.00
    Dr. Alan J. Main Ph.D., 60
    Exec. VP of Pharmaceutical Research
    362.00K0.00
    Dr. Pablo Lapuerta M.D., 51
    Chief Medical Officer and Exec. VP of Safety & Pharmacovigilance
    376.00K0.00
    Dr. Robert J. Lefkowitz M.D., 70
    Consultant, Director and Member of Corp. Governance Committee
    78.00KN/A
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders